Lung cancer patients get second chance with triple therapy combo

NCT ID NCT05401786

Ongoing Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of two immunotherapy drugs (ipilimumab and cemiplimab) plus targeted radiation can help people with advanced non-small cell lung cancer whose previous immunotherapy stopped working. The study enrolls 54 participants and aims to see if the treatment can shrink tumors or keep them stable for at least 6 months. The approach is based on earlier research suggesting these therapies work better together.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab, Cemiplimab, and Stereotactic Body Radiotherapy
What this could lead to: If it works, this could offer a new treatment option for people with advanced lung cancer whose current immunotherapy has stopped working.
What could go wrong: This is a small, early-phase trial with only 54 participants, so results may not apply to everyone. The combination also carries risks of immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Antoni van Leeuwenhoek - Netherlands Cancer Institute

Amsterdam, North Holland, 1066 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.